Patents by Inventor Daniel R. Deaver

Daniel R. Deaver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions having improved storage stability
    Patent number: 11969469
    Abstract: The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent.
    Type: Grant
    Filed: August 10, 2021
    Date of Patent: April 30, 2024
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver, Michael J. Palmieri, Jr., Zhengzheng Pan
  • PHARMACEUTICAL COMPOSITIONS COMPRISING SORBITAN ESTERS
    Publication number: 20240131024
    Abstract: The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.
    Type: Application
    Filed: October 31, 2023
    Publication date: April 25, 2024
    Inventors: Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver
  • Pharmaceutical Compositions Comprising Sorbitan Esters
    Publication number: 20240058327
    Abstract: The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.
    Type: Application
    Filed: March 14, 2023
    Publication date: February 22, 2024
    Inventors: Jason M. PERRY, Daniel R. DEAVER, Magali B. HICKEY, Julius F. REMENAR, Jennifer VANDIVER
  • Methods for treating antipsychotic-induced weight gain
    Patent number: 11793805
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: October 24, 2023
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel R. Deaver, Mark Todtenkopf
  • METHODS FOR TREATING DEPRESSIVE SYMPTOMS
    Publication number: 20230158017
    Abstract: The present application relates methods for treating a depressive symptom comprising administering an effective amount of a ? opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.
    Type: Application
    Filed: November 18, 2022
    Publication date: May 25, 2023
    Inventors: Laura Cook Blumberg, Daniel R. Deaver, David J. Eyerman, Thomas Andrew Wynn
  • Methods for treating depressive symptoms
    Patent number: 11534436
    Abstract: The present application relates methods for treating a depressive symptom comprising administering an effective amount of a ? opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: December 27, 2022
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Laura Cook Blumberg, Daniel R. Deaver, David J. Eyerman, Thomas Andrew Wynn
  • METHODS FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN
    Publication number: 20220280502
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Application
    Filed: October 20, 2021
    Publication date: September 8, 2022
    Inventors: Daniel R. Deaver, Mark Todtenkopf
  • Methods for treating antipsychotic-induced weight gain
    Patent number: 11351166
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: June 7, 2022
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel R. Deaver, Mark Todtenkopf
  • Pharmaceutical Compositions Having Improved Storage Stability
    Publication number: 20220072133
    Abstract: The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent
    Type: Application
    Filed: August 10, 2021
    Publication date: March 10, 2022
    Inventors: Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver, Michael J. Palmieri, JR., Zhengzheng Pan
  • Composition for treating mental illness
    Patent number: 11241425
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: February 8, 2022
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel R. Deaver, Mark Todtenkopf
  • Methods for treating antipsychotic-induced weight gain
    Patent number: 11185541
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: November 30, 2021
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel R. Deaver, Mark Todtenkopf
  • Pharmaceutical compositions having improved storage stability
    Patent number: 11097006
    Abstract: The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: August 24, 2021
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver, Michael J. Palmieri, Jr., Zhengzheng Pan
  • COMPOSITIONS OF BUPRENORPHINE AND ยต ANTAGONISTS
    Publication number: 20210196703
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; A ? A ? nAI = [ C m ? ? ax ? ( BUP ) / EC 50 ] [ C ma ? ? x ? ( ANTAGONIST ) / IC 50 ] .
    Type: Application
    Filed: October 6, 2020
    Publication date: July 1, 2021
    Inventors: Daniel R. Deaver, Elliot Ehrich
  • Methods for Treating Antipsychotic-Induced Weight Gain
    Publication number: 20210046065
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Application
    Filed: October 15, 2020
    Publication date: February 18, 2021
    Inventors: Daniel R. Deaver, Mark Todtenkopf
  • Methods for Treating Antipsychotic-Induced Weight Gain
    Publication number: 20210038594
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Application
    Filed: October 15, 2020
    Publication date: February 11, 2021
    Inventors: Daniel R. Deaver, Mark Todtenkopf
  • Methods for Treating Antipsychotic-Induced Weight Gain
    Publication number: 20210015812
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Application
    Filed: June 12, 2020
    Publication date: January 21, 2021
    Inventors: Daniel R. Deaver, Mark Todtenkopf
  • METHODS FOR TREATING DEPRESSIVE SYMPTOMS
    Publication number: 20210000818
    Abstract: The present application relates methods for treating a depressive symptom comprising administering an effective amount of a ? opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.
    Type: Application
    Filed: June 26, 2020
    Publication date: January 7, 2021
    Inventors: Laura Cook Blumberg, Daniel R. Deaver, David J. Eyerman, Thomas Andrew Wynn
  • Compositions of buprenorphine and ? antagonists
    Patent number: 10806731
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: October 20, 2020
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel R. Deaver, Elliot Ehrich
  • Pharmaceutical Compositions Having Improved Storage Stability
    Publication number: 20200268891
    Abstract: The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent
    Type: Application
    Filed: March 30, 2020
    Publication date: August 27, 2020
    Inventors: Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver, Michael J. Palmieri, JR., Zhengzheng Pan
  • Morphan and morphinan analogues, and methods of use
    Patent number: 10752592
    Abstract: The present application relates to analogues of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in need thereof.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: August 25, 2020
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Laura Cook Blumberg, Daniel R. Deaver, David J. Eyerman, Thomas Andrew Wynn